Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review.
Hind RafeiEhab El-BaheshAntoine FinianosMin-Ling L LiuGeraldine P SchechterPublished in: Case reports in hematology (2017)
Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBL with EPOCH chemotherapy and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further, literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses.
Keyphrases
- case report
- diffuse large b cell lymphoma
- human immunodeficiency virus
- epstein barr virus
- end stage renal disease
- clinical practice
- hepatitis c virus
- free survival
- antiretroviral therapy
- ejection fraction
- locally advanced
- newly diagnosed
- hiv infected
- peritoneal dialysis
- emergency department
- climate change
- rectal cancer
- bone marrow
- adverse drug
- replacement therapy
- cell therapy